{
    "root": "30b09e30-01bd-efc4-e063-6394a90aabc3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Irinotecan hydrochloide",
    "value": "20250319",
    "ingredients": [
        {
            "name": "LACTIC ACID, UNSPECIFIED FORM",
            "code": "33X04XA5AT"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "IRINOTECAN HYDROCHLORIDE",
            "code": "042LAQ1IIS"
        }
    ],
    "indications": "Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.\n                     Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.",
    "contraindications": "Colorectal cancer combination regimen 1: Irinotecan hydrochloride injection 125 mg/m 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 with LV 20 mg/m 2 intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks. ( 2.1 ) Colorectal cancer combination regimen 2: Irinotecan hydrochloride injection 180 mg/m 2 intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m 2 intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m 2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m 2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30. ( 2.1 ) Colorectal cancer single agent regimen 1: Irinotecan hydrochloride injection 125 mg/m 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. ( 2.2 ) Colorectal cancer single agent regimen 2: Irinotecan hydrochloride injection 350 mg/m 2 intravenous infusion over 90 minutes on day 1 every 3 weeks. ( 2.2 )",
    "warningsAndPrecautions": "Irinotecan hydrochloride injection, USP is supplied as a sterile, pale yellow, clear, aqueous solution and is available in single-dose brown glass vials in the following package sizes:\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 PRESENTATION\n                                 \n                              \n                           \n                           \n                              \n                                 NDC CODE\n                                 \n                              \n                           \n                        \n                        \n                           \n                              2 mL-fill vial containing 40 mg/2 mL (20 mg/mL) irinotecan hydrochloride injection \n      \n                              \n                           \n                           \n                              NDC 68001-480-35 \n      \n                              \n                           \n                        \n                        \n                           \n                              5 mL-fill vial containing 100 mg/5 mL (20 mg/mL) irinotecan hydrochloride injection \n      \n                              \n                           \n                           \n                              NDC 68001-480-22 \n      \n                              \n                           \n                        \n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Keep the vial in the carton until the time of use. \n  \n                       Inspect the vial for damage and visible signs of leaks before removing from the carton. If damaged, incinerate the unopened package.\n \n                  Irinotecan Hydrochloride is a hazardous drug. Follow special handling and disposal procedures\n \n  1.",
    "adverseReactions": "• Irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients."
}